Target intelligence / Profile preview

ADAMTS10 antisense RNA 1 (ADAMTS10-AS1)

Target
ADAMTS10-AS1
Molecular classification
Long non-coding RNA, Antisense RNA, Non-coding RNA
01

Overview

ADAMTS10 antisense RNA 1 (ADAMTS10-AS1) is a long non-coding RNA transcribed from the antisense strand of the ADAMTS10 gene locus. Like other antisense RNAs, it is believed to regulate the expression of its sense partner (in this case, ADAMTS10, which encodes a secreted metalloprotease involved in extracellular matrix organization and development) at transcriptional, post-transcriptional, or epigenetic levels. The precise biological and clinical relevance of ADAMTS10-AS1 is not well characterized, as specific studies on this lncRNA are lacking. However, the broader class of antisense RNAs is known to play diverse roles in regulating gene expression, affecting mRNA stability, translation, and, potentially, disease phenotypes such as cancer aggressiveness and neurodegeneration. ADAMTS10-AS1 is a non-coding antisense RNA, not a classic therapeutic target, with limited direct functional data, but notable as part of the broader regulatory landscape of long non-coding RNAs in gene expression modulation.

Other names
ADAMTS10-AS1
02

Mechanism of action

General mechanisms for antisense RNA targeting include the use of antisense oligonucleotides to induce RNase H-mediated RNA degradation, block translation, or modulate splicing.

03

Biological functions

Regulation of gene expression (via antisense regulation of the nearby protein-coding ADAMTS10 gene or potentially others)Epigenetic regulationRNA stability and translation regulation
04

Disease associations

Potential involvement in cancer progression or suppression (based on roles of other antisense lncRNAs, specific disease association for ADAMTS10-AS1 itself remains unclear)Other (as the field expands, some AS-lncRNAs are implicated in neurodegenerative disease and cardiovascular disease, but direct evidence for ADAMTS10-AS1 is currently lacking)
05

Safety considerations

Not established. General safety concerns for targeting non-coding RNAs include off-target effects and unintended gene regulation, but these are theoretical for ADAMTS10-AS1 at present.

Beyond the preview

Go deeper on ADAMTS10 antisense RNA 1 (ADAMTS10-AS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADAMTS10 antisense RNA 1 (ADAMTS10-AS1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call